Safety of Lumason® (SonoVue®) in special populations and critically ill patients
Frontiers in Cardiovascular Medicine · 02.08.2023 · 10
DOI: 10.3389/fcvm.2023.1225654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 02.08.2023. Verfasst von A Filippone und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical & Regulatory Affairs, Bracco Imaging SpA, Milan, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Evidence for the safe use of Lumason® (SonoVue®), an ultrasound enhancing agent (UEA), in special patient populations is critical to enable healthcare professionals to make informed decisions concerning its use in such patients. Herein, we provide insight on the safety and tolerability of Lumason® in special patient populations. Findings are presented from clinical pharmacology studies conducted in patients with compromised cardiopulmonary conditions, from a retrospective study performed in critically ill patients, and from post-marketing surveillance data from over 20 years of market use of Lumason® (SonoVue®). No detrimental effects of Lumason® on cardiac electrophysiology were observed in patients with coronary artery disease (CAD), and no significant effects on pulmonary hemodynamics were noted in patients with pulmonary hypertension or congestive heart failure. Similarly, no effects on several assessments of pulmonary function (e.g., FVC) were observed in patients with chronic obstructive pulmonary disease (COPD), and no clinically meaningful changes in O 2 saturation or other safety parameters were observed after administration of Lumason® to patients with diffuse interstitial pulmonary fibrosis (DIPF). The retrospective study of critically ill patients revealed no significant difference for in-hospital mortality between patients administered Lumason® for echocardiography versus those who had undergone echocardiography without contrast agent. Post-marketing surveillance revealed very low reporting rates (RR) for non-serious and serious adverse events and that serious hypersensitivity reactions were rare. These findings confirm that Lumason® is a safe and well tolerated UEA for use in special populations and critically ill patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Medical & Regulatory Affairs, Bracco Imaging SpA, Milan, Italy.
- Global Medical & Regulatory Affairs, Bracco Diagnostics Inc., Monroe, NJ, United States.
Zitieren
APA
Filippone, A., Kirchin, M. A., Monteith, J., Storto, M. L., & Spinazzi, A. (2023). Safety of Lumason® (SonoVue®) in special populations and critically ill patients. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1225654
Vancouver
Filippone A, Kirchin MA, Monteith J, Storto ML, Spinazzi A. Safety of Lumason® (SonoVue®) in special populations and critically ill patients. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1225654
BibTeX
@article{Filippone2023,
author = {Filippone, A and Kirchin, M A and Monteith, J and Storto, M L and Spinazzi, A},
title = {Safety of Lumason® (SonoVue®) in special populations and critically ill patients},
journal = {Frontiers in Cardiovascular Medicine},
year = {2023},
volume = {10},
doi = {10.3389/fcvm.2023.1225654}
}
EUVIMED